MacDermed Dhara M, Houtman Kristen M, Thang Sandy H, Allen Pamela K, Caudle Abigail S, Gainer Sarah M, Hunt Kelly K, Perkins George H, Shaitelman Simona F, Smith Benjamin D, Strom Eric A, Tereffe Welela, Woodward Wendy A, Buchholz Thomas A, Hoffman Karen E
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pract Radiat Oncol. 2014 Mar-Apr;4(2):116-122. doi: 10.1016/j.prro.2013.06.001. Epub 2013 Jul 12.
One interpretation of the American College of Surgeons Oncology Group Z0011 trial is that whole breast radiation therapy, known to treat a portion of the low axilla when delivered in the supine position, can treat residual microscopic disease in patients with involved axillary nodes that were not removed by axillary dissection. The purpose of this study was to quantify radiation dose delivered to the axilla for patients treated in the prone position.
We analyzed treatment plans from 40 consecutive patients who received radiation targeting the intact breast with tangent fields in the prone position. Axillary levels were contoured using Radiation Therapy Oncology Group (RTOG) definitions and radiation dose- volume calculations were made for axillary levels, heart, and lungs. We generated revised plans for 10 patients by modifying the tangent beams to increase axillary dose and compared original with modified plans.
The median proportion of the axilla covered by 90% of the prescription dose was 13% of level I (range, 0%-61%), 0% of level II (range, 0%-6%), and 0% of level III (range, 0%-0%). More of the level I axilla was covered in obese compared with nonobese patients (P = .013). Level I coverage did not differ significantly by laterality (P = .740) or tumor location (P = .527). Modification of the treatment plans significantly increased level I coverage (P = .005) with all modified plans delivering 90% of the prescription dose to at least 96% of the level I axilla. The modified plans had increased lung (P = .005) and heart (P = .028) dose, which were within acceptable RTOG normal tissue constraints.
Most patients treated with standard whole breast tangential radiation in the prone position receive subtherapeutic dose to the level I and II axilla. Patients treated in the prone position who require therapeutic radiation dose to the low axilla need treatment field modification; this is feasible for many patients using tangent fields.
美国外科医师学会肿瘤学组Z0011试验的一种解释是,已知在仰卧位进行全乳放射治疗时可治疗部分低位腋窝,对于腋窝淋巴结受累但未行腋窝清扫术的患者,该治疗可治疗残留的微小病灶。本研究的目的是量化俯卧位治疗患者腋窝所接受的放射剂量。
我们分析了40例连续接受俯卧位切线野全乳放疗患者的治疗计划。根据放射肿瘤学组(RTOG)的定义对腋窝水平进行轮廓勾画,并对腋窝水平、心脏和肺部进行放射剂量体积计算。我们通过修改切线野增加腋窝剂量,为10例患者生成了修订计划,并将原始计划与修订计划进行比较。
处方剂量的90%覆盖的腋窝中位比例为I级腋窝的13%(范围0%-61%),II级腋窝的0%(范围0%-6%),III级腋窝的0%(范围0%-0%)。与非肥胖患者相比,肥胖患者I级腋窝的覆盖范围更大(P = 0.013)。I级腋窝的覆盖范围在左右侧别(P = 0.740)或肿瘤位置(P = 0.527)方面无显著差异。治疗计划的修改显著增加了I级腋窝的覆盖范围(P = 0.005),所有修订计划均将处方剂量的90%输送至至少96%的I级腋窝。修订计划增加了肺部(P = 0.005)和心脏(P = 0.028)的剂量,这些剂量在RTOG可接受的正常组织限制范围内。
大多数接受俯卧位标准全乳切线放疗的患者,其I级和II级腋窝接受的剂量低于治疗剂量。需要对低位腋窝进行治疗性放射剂量的俯卧位治疗患者需要修改治疗野;对于许多使用切线野的患者来说,这是可行的。